« Return to News | Clinical Intelligence

GW receives Austrian approval for cannabis-based oral spray for MS

Friday, February 10, 2012 12:04 PM

GW Pharmaceuticals’ Sativex (THC and cannabidiol) oral spray has received regulatory approval in Austria as a treatment of spasticity due to Multiple Sclerosis (MS).

The launch of Sativex in Austria is expected during 2012, following completion of the national pricing and reimbursement process. Sativex will be marketed in Austria by GW's marketing partner, Almirall.

In addition, the request to expand Sativex to additional European countries has been validated and is now under technical review by regulatory authorities in Belgium, Finland, Iceland, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal and Slovakia. This process is expected to be complete by mid-2012.

Sativex is also in phase III clinical development as a treatment for cancer pain.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.